专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050013863A1 Dual drug dosage forms with improved separation of drugs 审中-公开
标题翻译：具有改善药物分离的双重药物剂型
公开(公告)号：US20050013863A1
公开(公告)日：2005-01-20
申请号：US10623481
申请日：2003-07-18
申请人： Jong Lim , John Shell , Jenny Louie-Helm
发明人： Jong Lim , John Shell , Jenny Louie-Helm
IPC分类号： A61K9/22 , A61K9/24
CPC分类号： A61K31/4415 , A61K9/0065 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/2853 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
摘要翻译：包含延长释放核心和速释层或壳的药物片剂在片剂的延长释放和速释部分之间用无药物聚合物的薄屏障层制备。阻隔层可被胃肠液渗透，从而使胃肠道液体完全进入延长释放核心，但在施用速释层期间保持完整，从而大大减少或消除了立即释放药物的渗透延长释放部分。

2. 发明授权

US08685450B2 Dual drug dosage forms with improved separation of drugs 有权
标题翻译：具有改善药物分离的双重药物剂型
公开(公告)号：US08685450B2
公开(公告)日：2014-04-01
申请号：US13530631
申请日：2012-06-22
申请人： Jong Lim , John N. Shell , Jenny Louie-Helm
发明人： Jong Lim , John N. Shell , Jenny Louie-Helm
IPC分类号： A61K9/22 , A61K9/24
CPC分类号： A61K31/4415 , A61K9/0065 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/2853 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
摘要翻译：包含延长释放核心和速释层或壳的药物片剂在片剂的延长释放和速释部分之间用无药物聚合物的薄屏障层制备。阻隔层可被胃肠液渗透，从而使胃肠道液体完全进入延长释放核心，但在施用速释层期间保持完整，从而大大减少或消除了立即释放药物的渗透延长释放部分。

3. 发明申请

US20120263792A1 DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS 有权
标题翻译：双剂量剂型改进分离药物
公开(公告)号：US20120263792A1
公开(公告)日：2012-10-18
申请号：US13530631
申请日：2012-06-22
申请人： JONG LIM , John N. Shell , Jenny Louie-Helm
发明人： JONG LIM , John N. Shell , Jenny Louie-Helm
IPC分类号： A61K9/00 , A61K9/14 , A61K31/4965 , A61K31/426 , A61K31/4015 , A61K31/18
CPC分类号： A61K31/4415 , A61K9/0065 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/2853 , A61K31/00 , A61K31/155 , A61K31/40 , A61K31/4015 , A61K45/06 , A61K2300/00
摘要： Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing lull access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.
摘要翻译：包含延长释放核心和速释层或壳的药物片剂在片剂的延长释放和速释部分之间用无药物聚合物的薄屏障层制备。阻隔层可被胃肠道液体穿透，从而使胃肠道液体延伸到延长释放核心，但在施用速释层期间保持完整，从而显着减少或消除了立即释放药物的任何渗透延长释放部分。

4. 发明授权

US5972389A Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter 失效
标题翻译：用于控制释放微溶药物和不溶物质的保持性口服药物剂型
公开(公告)号：US5972389A
公开(公告)日：1999-10-26
申请号：US716906
申请日：1996-09-19
申请人： John W. Shell , Jenny Louie-Helm
发明人： John W. Shell , Jenny Louie-Helm
IPC分类号： A61K9/00 , A61K9/127 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/48 , A61K9/50 , A61K9/52 , A61K47/30 , A61K47/34
CPC分类号： A61K9/0065 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2031 , A61K9/2054 , A61K9/2081 , A61K9/127 , A61K9/4808 , A61K9/5026
摘要： Controlled-release oral drug dosage forms that comprise a tablet or capsule containing a plurality of particles of a solid-state drug dispersed in a swellable/erodible polymer, such as poly(ethylene oxide) are described. Once ingested, the tablet or capsule disintegrates to disperse the particles within the stomach where they imbibe water to cause them to swell and promote retention in fed-mode-induced patients. As the gastric-retained dosage form gradually erodes, the drug is released in a controlled manner to the stomach for treatment of local disorders, and to the upper gastrointestinal tract where it becomes available for absorption in a controlled and therapeutic manner. Drug-containing vesicles, such as liposomes or nanoparticles or enteric-coated drug particles, can also be delivered to the gastrointestinal tract in a controlled manner using the gastric-retentive dosage forms of the present invention.
摘要翻译：描述了包含分散在可溶胀/可溶性聚合物例如聚（环氧乙烷）中的多个固态药物颗粒的片剂或胶囊的控制释放的口服药物剂型。一旦摄取，片剂或胶囊就会崩解，将颗粒分散在胃中，在那里它们吸收水分，使其在喂食模式诱发的患者中膨胀并促进保留。当胃保留剂型逐渐消失时，药物以受控的方式释放到胃中用于治疗局部疾病，并向上消化道以可控和治疗的方式吸收。含有药物的小泡，例如脂质体或纳米颗粒或肠溶包衣的药物颗粒也可以使用本发明的保持性剂型以受控的方式递送至胃肠道。

5. 发明授权

US09980903B2 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract 有权
公开(公告)号：US09980903B2
公开(公告)日：2018-05-29
申请号：US13153211
申请日：2011-06-03
申请人： Bret Berner , Jenny Louie-Helm , John W. Shell , Barbara Shell
发明人： Bret Berner , Jenny Louie-Helm , John W. Shell
IPC分类号： A61K9/20 , A61K31/197 , A61K9/00 , A61K31/00 , A61K31/65 , A61K31/195 , A61K31/496
CPC分类号： A61K9/0065 , A61K9/20 , A61K9/2031 , A61K31/00 , A61K31/195 , A61K31/197 , A61K31/496 , A61K31/65 , Y02A50/473 , Y02A50/475 , Y02A50/481
摘要： Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.

6. 发明申请

US20110236485A1 SHELL AND CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE 有权
标题翻译：壳和核心剂量形式进行零售药物释放
公开(公告)号：US20110236485A1
公开(公告)日：2011-09-29
申请号：US13156225
申请日：2011-06-08
申请人： BRET BERNER , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： BRET BERNER , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/14 , A61K31/155 , A61P3/10 , A61K31/675 , A61K31/616 , A61P31/00
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

7. 发明授权

US07736667B2 Shell-and-core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US07736667B2
公开(公告)日：2010-06-15
申请号：US10213823
申请日：2002-08-07
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。外壳还通过在胃液吸收到在餐后或喂食模式下保留在胃中的尺寸时膨胀而促进剂型的胃滞留。

8. 发明授权

US06488962B1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 有权
标题翻译：片剂形状以增强可膨胀控释口服剂型的胃滞留
公开(公告)号：US06488962B1
公开(公告)日：2002-12-03
申请号：US09598061
申请日：2000-06-20
申请人： Bret Berner , Jenny Louie-Helm
发明人： Bret Berner , Jenny Louie-Helm
IPC分类号： A61K914
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2072
摘要： The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
摘要翻译：口服药物剂型在胃中的保留通过使用可膨胀的剂型来改善，其可以以防止它们因特定方向而无意地穿过幽门的方式成型。形状的平面突起是具有不同长度的两个正交轴的平面突起，其长度足够短以允许在肿胀之前容易吞咽，而较短的时间足以在半小时内膨胀以防止通过幽门。

9. 发明授权

US06340475B2 Extending the duration of drug release within the stomach during the fed mode 有权
标题翻译：在喂食模式期间延长胃内药物释放的持续时间
公开(公告)号：US06340475B2
公开(公告)日：2002-01-22
申请号：US09282233
申请日：1999-03-29
申请人： John W. Shell , Jenny Louie-Helm , Micheline Markey
发明人： John W. Shell , Jenny Louie-Helm , Micheline Markey
IPC分类号： A61K926
CPC分类号： A61K9/0065 , A61K9/2013 , A61K9/2031 , A61K9/205 , A61K9/2054
摘要： Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.
摘要翻译：将药物配制成单位口服剂型，通过将它们并入由亲水性聚合物组成的聚合物基质中，所述亲水性聚合物在吸水时膨胀至足够大以在给药模式期间促进剂型在胃中的保留。口服制剂设计用于胃内保留和控制递送并入药物进入胃腔，并因此施用，通过溶液扩散将药物从基质释放到胃液中。已经达到足够大小的溶胀的聚合物基质在患者处于喂养模式的同时在胃腔内保留数小时，并保持完整的时间足以使基本上所有的药物在基质溶解之前被释放出来。溶胀基质降低胃液对药物的可及性，从而降低药物释放速率。该方法与通过选择特定聚合物，聚合物分子量和其他变量的扩散阻滞一起导致药物持续且受控制的胃腔输送速率。

10. 发明授权

US08329215B2 Shell and core dosage form approaching zero-order drug release 有权
标题翻译：壳和核心剂型接近零级药物释放
公开(公告)号：US08329215B2
公开(公告)日：2012-12-11
申请号：US13156225
申请日：2011-06-08
申请人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
发明人： Bret Berner , Jenny Louie-Helm , Gloria Gusler , John N. Shell
IPC分类号： A61K9/52 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/0002 , A61K9/2027 , A61K9/284 , A61K9/2853 , A61K31/155 , A61K31/472 , A61K31/525 , A61K31/60
摘要： Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
摘要翻译：将药物配制成用于控制释放的口服剂型，其中释放速率限制部分是围绕药物含核心的壳。壳体通过允许药物从核心扩散而释放出核心的药物。该外壳还通过在胃液吸入胃中在餐后或喂食模式下保留在胃中的大小时肿胀而使胃滞留。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式